WO2016006241A1 - Anti-canine pd-1 antibody or anti-canine pd-l1 antibody - Google Patents
Anti-canine pd-1 antibody or anti-canine pd-l1 antibody Download PDFInfo
- Publication number
- WO2016006241A1 WO2016006241A1 PCT/JP2015/003444 JP2015003444W WO2016006241A1 WO 2016006241 A1 WO2016006241 A1 WO 2016006241A1 JP 2015003444 W JP2015003444 W JP 2015003444W WO 2016006241 A1 WO2016006241 A1 WO 2016006241A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- seq
- canine
- sequence shown
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
(1)配列番号1に示されるアミノ酸配列からなるイヌPD-1に特異的に結合する、以下の(a)又は(b)記載の抗イヌPD-1抗体。
(a)配列番号2に示されるアミノ酸配列、又は配列番号2に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号3に示されるアミノ酸配列、又は配列番号3に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
(b)配列番号4に示されるアミノ酸配列、又は配列番号4に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号5に示されるアミノ酸配列、又は配列番号5に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
(2)配列番号6に示されるアミノ酸配列からなるイヌPD-L1に特異的に結合する、以下の(c)又は(d)記載の抗イヌPD-L1抗体。
(c)配列番号7に示されるアミノ酸配列、又は配列番号7に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号8に示されるアミノ酸配列、又は配列番号8に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
(d)配列番号9に示されるアミノ酸配列、又は配列番号9に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号10に示されるアミノ酸配列、又は配列番号10に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
(3)配列番号1に示されるアミノ酸配列からなるイヌPD-1に特異的に結合する、以下の(e)又は(f)記載の抗イヌPD-1抗体。
(e)配列番号11に示されるアミノ酸配列からなるCDR1、配列番号12に示されるアミノ酸配列からなるCDR2及び配列番号13に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号14に示されるアミノ酸配列からなるCDR1、配列番号15に示されるアミノ酸配列からなるCDR2及び配列番号16に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
(f)配列番号17に示されるアミノ酸配列からなるCDR1、配列番号18に示されるアミノ酸配列からなるCDR2及び配列番号19に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号20に示されるアミノ酸配列からなるCDR1、配列番号21に示されるアミノ酸配列からなるCDR2及び配列番号22に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
(4)配列番号6に示されるアミノ酸配列からなるイヌPD-L1に特異的に結合する、以下の(g)又は(h)記載の抗イヌPD-L1抗体。
(g)配列番号23に示されるアミノ酸配列からなるCDR1、配列番号24に示されるアミノ酸配列からなるCDR2及び配列番号25に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号26に示されるアミノ酸配列からなるCDR1、配列番号27に示されるアミノ酸配列からなるCDR2及び配列番号28に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
(h)配列番号29に示されるアミノ酸配列からなるCDR1、配列番号30に示されるアミノ酸配列からなるCDR2及び配列番号31に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号32に示されるアミノ酸配列からなるCDR1、配列番号33に示されるアミノ酸配列からなるCDR2及び配列番号34に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
(5)上記(1)~(4)のいずれか記載の抗体を含有することを特徴とするイヌPD-1とイヌPD-L1との結合阻害剤。
(6)上記(1)~(4)のいずれか記載の抗体を用いることを特徴とするイヌPD-1とイヌPD-L1との結合阻害方法。
(7)上記(1)~(4)のいずれか記載の抗体をコードする遺伝子。 That is, the present invention is as disclosed below.
(1) The anti-canine PD-1 antibody described in (a) or (b) below, which specifically binds to canine PD-1 consisting of the amino acid sequence represented by SEQ ID NO: 1.
(A) the amino acid sequence shown in SEQ ID NO: 2, or the heavy chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 2, and the amino acid sequence shown in SEQ ID NO: 3, or An anti-canine PD-1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 3;
(B) the heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 4, or the amino acid sequence shown in SEQ ID NO: 4 having 90% or more identity, and the amino acid sequence shown in SEQ ID NO: 5, or An anti-canine PD-1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 5;
(2) The anti-canine PD-L1 antibody described in (c) or (d) below, which specifically binds to canine PD-L1 consisting of the amino acid sequence represented by SEQ ID NO: 6.
(C) the amino acid sequence shown in SEQ ID NO: 7, or the heavy chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 7, and the amino acid sequence shown in SEQ ID NO: 8, or An anti-canine PD-L1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 8;
(D) the amino acid sequence shown in SEQ ID NO: 9, or the heavy chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 9, and the amino acid sequence shown in SEQ ID NO: 10, or An anti-canine PD-L1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 10;
(3) The anti-canine PD-1 antibody described in (e) or (f) below, which specifically binds to canine PD-1 consisting of the amino acid sequence represented by SEQ ID NO: 1.
(E) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 11, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 12 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 13, An anti-canine PD-1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 15, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 16. antibody;
(F) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 18 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 19, An anti-canine PD-1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 21, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 22 antibody;
(4) The anti-canine PD-L1 antibody described in (g) or (h) below, which specifically binds to canine PD-L1 consisting of the amino acid sequence represented by SEQ ID NO: 6.
(G) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 23, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 24 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 25; An anti-canine PD-L1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 27, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 28 antibody;
(H) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 29, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 30 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 31, An anti-canine PD-L1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 33, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 34 antibody;
(5) A binding inhibitor between canine PD-1 and canine PD-L1, comprising the antibody according to any one of (1) to (4) above.
(6) A method for inhibiting binding between canine PD-1 and canine PD-L1, comprising using the antibody according to any one of (1) to (4) above.
(7) A gene encoding the antibody according to any one of (1) to (4) above.
(a)配列番号2に示されるアミノ酸配列、又は配列番号2に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号3に示されるアミノ酸配列、又は配列番号3に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
(b)配列番号4に示されるアミノ酸配列、又は配列番号4に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号5に示されるアミノ酸配列、又は配列番号5に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
の(a)又は(b)記載の抗イヌPD-1抗体であれば特に制限されないが、
(a’)配列番号2に示されるアミノ酸配列、又は配列番号2に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列からなる重鎖可変領域、及び配列番号3に示されるアミノ酸配列、又は配列番号3に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列からなる軽鎖可変領域とを備えたことを特徴とする抗イヌPD-1抗体;(b’)配列番号4に示されるアミノ酸配列、又は配列番号4に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列からなる重鎖可変領域、及び配列番号5に示されるアミノ酸配列、又は配列番号5に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列からなる軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
の(a’)又は(b’)記載の抗イヌPD-1抗体であることが好ましく、かかる抗イヌPD-1抗体はイヌPD-1を認識して結合可能であることから、イヌPD-1の発現解析や機能解析が可能となるほか、イヌPD-1とイヌPD-L1との結合を阻害することが可能となる。 The anti-canine PD-1 antibody of the present invention specifically binds to canine PD-1 consisting of the amino acid sequence shown in SEQ ID NO: 1,
(A) the amino acid sequence shown in SEQ ID NO: 2, or the heavy chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 2, and the amino acid sequence shown in SEQ ID NO: 3, or An anti-canine PD-1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 3;
(B) the heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 4, or the amino acid sequence shown in SEQ ID NO: 4 having 90% or more identity, and the amino acid sequence shown in SEQ ID NO: 5, or An anti-canine PD-1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 5;
The anti-canine PD-1 antibody described in (a) or (b) is not particularly limited,
(A ′) the amino acid sequence shown in SEQ ID NO: 2, or the heavy chain variable region consisting of an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 2, and the amino acid sequence shown in SEQ ID NO: 3, Or an anti-canine PD-1 antibody comprising a light chain variable region comprising an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 3; (b ′) SEQ ID NO: 4 A heavy chain variable region comprising the amino acid sequence shown, or an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 4, and the amino acid sequence shown in SEQ ID NO: 5, or the amino acid shown in SEQ ID NO: 5 An anti-canine PD-1 antibody comprising a light chain variable region comprising an amino acid sequence having 90% or more identity with the sequence;
It is preferable that the anti-canine PD-1 antibody described in (a ′) or (b ′) of the above is used, and since such anti-canine PD-1 antibody can recognize and bind to canine PD-1, In addition to the expression analysis and functional analysis of 1, it is possible to inhibit the binding between canine PD-1 and canine PD-L1.
(c)配列番号7に示されるアミノ酸配列、又は配列番号7に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号8に示されるアミノ酸配列、又は配列番号8に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
(d)配列番号9に示されるアミノ酸配列、又は配列番号9に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号10に示されるアミノ酸配列、又は配列番号10に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
の(c)又は(d)記載の抗イヌPD-L1抗体であれば特に制限されないが、
(c’)配列番号7に示されるアミノ酸配列、又は配列番号7に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列からなる重鎖可変領域、及び配列番号8に示されるアミノ酸配列、又は配列番号8に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列からなる軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;(d’)配列番号9に示されるアミノ酸配列、又は配列番号9に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列からなる重鎖可変領域、及び配列番号10に示されるアミノ酸配列、又は配列番号10に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列からなる軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
の(c’)又は(d’)記載の抗イヌPD-L1抗体であることが好ましく、かかる抗イヌPD-L1抗体はイヌPD-L1を認識して結合可能であることから、イヌPD-L1の発現解析や機能解析が可能となるほか、イヌPD-1とイヌPD-L1との結合を阻害することが可能となる。 The anti-canine PD-L1 antibody of the present invention specifically binds to canine PD-L1 consisting of the amino acid sequence shown in SEQ ID NO: 6,
(C) the amino acid sequence shown in SEQ ID NO: 7, or the heavy chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 7, and the amino acid sequence shown in SEQ ID NO: 8, or An anti-canine PD-L1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 8;
(D) the amino acid sequence shown in SEQ ID NO: 9, or the heavy chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 9, and the amino acid sequence shown in SEQ ID NO: 10, or An anti-canine PD-L1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 10;
The anti-canine PD-L1 antibody described in (c) or (d) is not particularly limited,
(C ′) the amino acid sequence shown in SEQ ID NO: 7, or the heavy chain variable region comprising an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 7, and the amino acid sequence shown in SEQ ID NO: 8, Or an anti-canine PD-L1 antibody comprising a light chain variable region comprising an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 8; (d ′) shown in SEQ ID NO: 9 A heavy chain variable region comprising an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 9, and the amino acid sequence shown in SEQ ID NO: 10, or the amino acid sequence shown in SEQ ID NO: 10 An anti-canine PD-L1 antibody comprising a light chain variable region consisting of an amino acid sequence having 90% identity or greater;
The anti-canine PD-L1 antibody described in (c ′) or (d ′) is preferably used. Since such an anti-canine PD-L1 antibody can recognize and bind to canine PD-L1, In addition to being able to analyze the expression and function of L1, it is possible to inhibit the binding between canine PD-1 and canine PD-L1.
(e)配列番号11に示されるアミノ酸配列からなるCDR1、配列番号12に示されるアミノ酸配列からなるCDR2及び配列番号13に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号14に示されるアミノ酸配列からなるCDR1、配列番号15に示されるアミノ酸配列からなるCDR2及び配列番号16に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
(f)配列番号17に示されるアミノ酸配列からなるCDR1、配列番号18に示されるアミノ酸配列からなるCDR2及び配列番号19に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号20に示されるアミノ酸配列からなるCDR1、配列番号21に示されるアミノ酸配列からなるCDR2及び配列番号22に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
の(e)又は(f)記載の抗イヌPD-1抗体を挙げることができる。 As another aspect of the anti-canine PD-1 antibody of the present invention, it specifically binds to canine PD-1 consisting of the amino acid sequence shown in SEQ ID NO: 1,
(E) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 11, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 12 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 13, An anti-canine PD-1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 15, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 16. antibody;
(F) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 18 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 19, An anti-canine PD-1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 21, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 22 antibody;
(E) or (f) of the anti-canine PD-1 antibody.
(g)配列番号23に示されるアミノ酸配列からなるCDR1、配列番号24に示されるアミノ酸配列からなるCDR2及び配列番号25に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号26に示されるアミノ酸配列からなるCDR1、配列番号27に示されるアミノ酸配列からなるCDR2及び配列番号28に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
(h)配列番号29に示されるアミノ酸配列からなるCDR1、配列番号30に示されるアミノ酸配列からなるCDR2及び配列番号31に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号32に示されるアミノ酸配列からなるCDR1、配列番号33に示されるアミノ酸配列からなるCDR2及び配列番号34に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
の(g)又は(h)記載の抗イヌPD-L1抗体を挙げることができる。 In another embodiment of the anti-canine PD-L1 antibody of the present invention, the anti-canine PD-L1 antibody specifically binds to canine PD-L1 consisting of the amino acid sequence represented by SEQ ID NO:
(G) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 23, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 24 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 25; An anti-canine PD-L1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 27, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 28 antibody;
(H) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 29, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 30 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 31, An anti-canine PD-L1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 33, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 34 antibody;
(G) or (h) of the anti-canine PD-L1 antibody.
1.cPD1又はcPDL1のcDNAクローニング
(プライマーの設計)
cPD1のcDNAを増幅するためのフォワードプライマー(YTM1142:配列番号43)とリバースプライマー(YTM1143:配列番号44)は、NCBI(http://www.ncbi.nlm.nih.gov/guide/) Accession No.XM_543338の配列に基づいて設計し、cPDL1のcDNAsを増幅するためのフォワードプライマー(YTM1144:配列番号45)とリバースプライマー(YTM1145:配列番号46)は、NCBI Accession No.XM_005615936.1の配列に基づいて設計した。なお、Accession No.XM_543338及びAccession No.XM_005615936.1の配列は、イヌにおいて発現が確認されていない遺伝子である。 [Production of rat monoclonal antibody against cPD1 or cPDL1]
1. cDNA cloning of cPD1 or cPDL1 (design of primers)
The forward primer (YTM1142: SEQ ID NO: 43) and reverse primer (YTM1143: SEQ ID NO: 44) for amplifying the cDNA of cPD1 are NCBI (http://www.ncbi.nlm.nih.gov/guide/) Accession No. . A forward primer (YTM1144: SEQ ID NO: 45) and a reverse primer (YTM1145: SEQ ID NO: 46) for amplifying cPDL1 cDNAs designed based on the sequence of XM — 543338 are NCBI Accession No. Designed based on the sequence of XM — 005615936.1. In addition, Accession No. XM — 543338 and Accession No. The sequence of XM — 005615936.1 is a gene whose expression has not been confirmed in dogs.
上記プライマー対を用い、正常なイヌの胸腺のcDNAをテンプレートとし、KOD-Plus-Neo(東洋紡社製)を用い、その添付のプロトコールに従ってcPD1遺伝子とcPDL1遺伝子を増幅した。PCRは、プレ変性を94℃で2分行い、その後98℃で10秒の変性、58℃で30秒のアニーリング、68℃で60秒の伸長を35サイクル行い、さらに最終伸長を68℃で10分行った。 (PCR reaction)
Using the above primer pair, normal canine thymus cDNA was used as a template, and KPD-Plus-Neo (manufactured by Toyobo Co., Ltd.) was used to amplify the cPD1 gene and the cPDL1 gene according to the attached protocol. In PCR, pre-denaturation was performed at 94 ° C. for 2 minutes, followed by 35 cycles of denaturation at 98 ° C. for 10 seconds, annealing at 58 ° C. for 30 seconds, extension at 68 ° C. for 60 seconds, and final extension at 68 ° C. I went for a minute.
上記で調製したPCR産物をゲル精製し、pBluescript SK(-)ベクターのSmaI部位に挿入し、インサートとしてcPD1又はcPDL1遺伝子を含むコンストラクトベクター(pBS-cPD1、pBS-cPDL1)を作製した。かかるコンストラクトベクターはフォワードプライマー(M13(-20):配列番号47)とリバースプライマー(M13 reverse:配列番号48)を用い、BigDye(登録商標)Termination v3.1 Cycle Sequencing Kit (Perkin-Elmer社製)及びABI Prism(登録商標)377自動DNAシークエンサー(Applied Biosystems社製)によって塩基配列を決定した。得られたcPD1の塩基配列及びその塩基配列がコードするアミノ酸配列を図1に、cPDL1の塩基配列及びその塩基配列がコードするアミノ酸配列を図2に示すと共に、cPD1の塩基配列を配列番号49、アミノ酸配列を配列番号1に、cPDL1の塩基配列を配列番号50、アミノ酸配列を配列番号6に示す。 (Insertion into vector and determination of nucleotide sequence)
The PCR product prepared above was gel-purified and inserted into the SmaI site of the pBluescript SK (−) vector, and construct vectors (pBS-cPD1, pBS-cPDL1) containing cPD1 or cPDL1 gene as inserts were prepared. Such a construct vector uses a forward primer (M13 (-20): SEQ ID NO: 47) and a reverse primer (M13 reverse: SEQ ID NO: 48), and BigDye (registered trademark) Termination v3.1 Cycle Sequencing Kit (manufactured by Perkin-Elmer). The nucleotide sequence was determined using an ABI Prism (registered trademark) 377 automatic DNA sequencer (Applied Biosystems). The resulting cPD1 base sequence and the amino acid sequence encoded by the base sequence are shown in FIG. 1, the base sequence of cPDL1 and the amino acid sequence encoded by the base sequence are shown in FIG. 2, and the base sequence of cPD1 is SEQ ID NO: 49, The amino acid sequence is shown in SEQ ID NO: 1, the base sequence of cPDL1 is shown in SEQ ID NO: 50, and the amino acid sequence is shown in SEQ ID NO: 6.
(cPD1又はcPDL1発現ベクターの構築)
cPD1又はcPDL1タンパク質を過剰発現するレトロウイルスベクターを構築した。まず、cPD1の配列とcPDL1の配列のC末端に2つのFLAGタグ配列を加えるため、cPD1の増幅には、pBS-cPD1をテンプレートとし、フォワードプライマー(YTM1142:配列番号43)と、cPD1配列のC末端にFLAGタグ配列を含むリバースプライマー(YTM1167:配列番号51)とを用い、cPDL1の増幅には、pBS-cPDL1をテンプレートとし、フォワードプライマー(YTM1144:配列番号45)と、cPDL1配列のC末端にFLAGタグ配列を含むリバースプライマー(YTM1168:配列番号52)を用いて一次PCRを行った。 2. Preparation of rat monoclonal antibody (construction of cPD1 or cPDL1 expression vector)
Retroviral vectors that overexpress cPD1 or cPDL1 protein were constructed. First, since two FLAG tag sequences are added to the C-terminus of the cPD1 sequence and the cPDL1 sequence, the amplification of cPD1 uses pBS-cPD1 as a template, a forward primer (YTM1142: SEQ ID NO: 43), and the CPD1 sequence C A reverse primer containing a FLAG tag sequence at the end (YTM1167: SEQ ID NO: 51) was used. For amplification of cPDL1, pBS-cPDL1 was used as a template, forward primer (YTM1144: SEQ ID NO: 45), and C-terminal of the cPDL1 sequence. Primary PCR was performed using a reverse primer containing a FLAG tag sequence (YTM1168: SEQ ID NO: 52).
一般的なトランスフェクション方法によって、pMx-IP-cPD1-FL、pMx-IP-cPDL1-FL#9をNRK細胞にトランスフェクトし、cPD1を安定発現するNRK細胞、cPDL1を安定発現するNRK細胞を作製した。まず、トランスフェクションを行う1日前にNRK細胞(3.5×105個)を6ウェルディッシュに播種した。細胞のトランスフェクションは、Lipofectamine 2000(Invitrogen社製)を用い、添付のプロトコールに従って行った。トランスフェクション後の細胞を48時間インキュベートし、その後、安定な形質導入細胞を得るために7.5μg/mlのプロマイシン(Sigma-Aldrich社製)の存在下で培養し、cPD1を安定発現するNRK細胞(NRK/cPD1)、cPDL1を安定発現するNRK細胞(NRK/cPDL1)を作製した。 (Production of transduced cells)
Using general transfection methods, pKx-IP-cPD1-FL and pMx-IP-cPDL1-
cPD1又はcPDL1に対するラットモノクローナル抗体を作製するために、上述で作製したNRK/cPD1又はNRK/cPDL1(500μlの上記DMEM培地中、1×107個)を等量のTiter Max(登録商標)Gold(CytRx社製)で乳化し、7週齢のSprague-Dawleyラット(九動社製)の後足蹠に皮肉投与した。投与から2週間後に、膝窩のリンパ節細胞を単離し、P3U1細胞と融合させた。すなわち、リンパ節単球細胞(1×108個)とP3U1細胞(2×107個)と混合し、無血清のRPMI1640培地で2回洗浄した。上澄みを除去後、細胞を37℃で2分インキュベートし、37℃の0.5mlポリエチレングリコール1500(Roche Diagnostics社製)を加え、さらに37℃の9ml無血清RPMI1640培地を加え、900rpmで5分、室温にて遠心した。上澄みを除去後、10%FBSとhypoxanthine-aminopterin-thymidine(HAT:Life Technologies社製)を含む36mlのGIT培地(和光純薬工業社製)で懸濁し、加湿インキュベーターにより、5%CO2ガス濃度下、37℃で1時間培養した。4mlのBM-Condimed H1培地(Roche Diagnostics社製)を加え、細胞を4つの96ウェル組織培養プレートに播種(100μl/ウェル)して培養した。コロニーが得られた後、cPD1又はcPDL1を発現するNRK細胞陽性ハイブリドーマをELISA法やフローサイトメトリーで同定し、かかるハイブリドーマを限定希釈によりクローニングし、cPD1を発現するNRK細胞陽性ハイブリドーマとしてハイブリドーマ3B7-D9、ハイブリドーマ4F12-E6、cPDL1を発現するNRK細胞陽性ハイブリドーマとしてハイブリドーマH7-9、ハイブリドーマG11-6を得た。以後、ハイブリドーマ3B7-D9によって産生された抗体を「3B7-D9」、ハイブリドーマ4F12-E6によって産生された抗体を「4F12-E6」、ハイブリドーマH7-9によって産生された抗体を「H7-9」、ハイブリドーマG11-6によって産生された抗体を「G11-6」ともいう。なお、ハイブリドーマ3B7-D9、4F12-E6、H7-9、G11-6は国立大学法人山口大学共同獣医学部に保管されており、一定の条件下で分譲可能である。 (Production of rat monoclonal antibody)
In order to produce a rat monoclonal antibody against cPD1 or cPDL1, NRK / cPD1 or NRK / cPDL1 prepared above (1 × 10 7 cells in 500 μl of the above-mentioned DMEM medium) was used in an equal amount of Titer Max® Gold ( CytRx) was emulsified and sarcastically administered to the hind footpad of 7-week-old Sprague-Dawley rats (Kudo Co., Ltd.). Two weeks after administration, popliteal lymph node cells were isolated and fused with P3U1 cells. Specifically, lymph node monocytic cells (1 × 10 8 cells) and P3U1 cells (2 × 10 7 cells) were mixed and washed twice with serum-free RPMI 1640 medium. After removing the supernatant, the cells were incubated at 37 ° C. for 2 minutes, 0.5 ml polyethylene glycol 1500 (Roche Diagnostics) at 37 ° C. was added, 9 ml serum-free RPMI 1640 medium at 37 ° C. was added, and 900 rpm for 5 minutes. Centrifuge at room temperature. After removing the supernatant, it is suspended in 36 ml of GIT medium (manufactured by Wako Pure Chemical Industries, Ltd.) containing 10% FBS and hypoxanthine-aminopterin-thymidine (HAT: manufactured by Life Technologies), and 5% CO 2 gas concentration by a humidified incubator. Then, the cells were cultured at 37 ° C. for 1 hour. 4 ml of BM-Condimed H1 medium (Roche Diagnostics) was added, and the cells were seeded (100 μl / well) in four 96-well tissue culture plates and cultured. After colonies are obtained, NRK cell positive hybridomas expressing cPD1 or cPDL1 are identified by ELISA or flow cytometry, and such hybridomas are cloned by limited dilution and hybridomas 3B7-D9 as NRK cell positive hybridomas expressing cPD1. Hybridoma H7-9 and hybridoma G11-6 were obtained as NRK cell positive hybridomas expressing hybridoma 4F12-E6 and cPDL1. Hereinafter, the antibody produced by the hybridoma 3B7-D9 is “3B7-D9”, the antibody produced by the hybridoma 4F12-E6 is “4F12-E6”, the antibody produced by the hybridoma H7-9 is “H7-9”, The antibody produced by the hybridoma G11-6 is also referred to as “G11-6”. The hybridomas 3B7-D9, 4F12-E6, H7-9, and G11-6 are stored in the National University Corporation Yamaguchi University Joint Veterinary School and can be distributed under certain conditions.
(抗体濃度及び細胞数)
cPD1に対するラットモノクローナル抗体である3B7-D9、4F12-E6と、上記で作製したNRK/cPD1との結合や、cPDL1に対するラットモノクローナル抗体であるH7-9、G11-6と、上記で作製したNRK/cPDL1との結合を、以下に示すフローサイトメトリー解析により調べた。各ラットモノクローナル抗体の濃度は0、0.04、0.156、0.625、2.5、10μg/mlであり、NRK/cPD1(2×105個)又はNRK/cPDL1(2×105個)を用いた。 [Confirmation of anti-cPD1 antibody or anti-cPDL1 antibody]
(Antibody concentration and cell number)
Binding of rat monoclonal antibodies against cPD1 3B7-D9, 4F12-E6 to NRK / cPD1 prepared above, rat monoclonal antibodies H7-9, G11-6 against cPDL1, and NRK / Binding to cPDL1 was examined by flow cytometry analysis shown below. The concentration of each rat monoclonal antibody is 0, 0.04, 0.156, 0.625, 2.5, 10 μg / ml, and NRK / cPD1 (2 × 10 5 cells) or NRK / cPDL1 (2 × 10 5 cells). Were used.
フローサイトメトリー解析に用いる細胞株の染色は次の文献(Mizuno et al., J Vet Med Sci, 71(12):1561-1568, 2009)に記載の方法に従って行った。一次抗体としては、精製したcPD1又はcPDL1に対する各ラットモノクローナル抗体を用いた。二次抗体としては抗ラットIgG-PE(Southern biotech社製)を用いた。サンプルはBD AccuriC6 (BD Bioscience社製)を用いて解析し、得られた結果をFlowJo software (Treestar社製)によって解析した。 (Flow cytometry analysis)
Staining of cell lines used for flow cytometry analysis was performed according to the method described in the following literature (Mizuno et al., J Vet Med Sci, 71 (12): 1561-1568, 2009). As the primary antibody, each rat monoclonal antibody against purified cPD1 or cPDL1 was used. As a secondary antibody, anti-rat IgG-PE (manufactured by Southern biotech) was used. Samples were analyzed using BD AccuriC6 (BD Bioscience), and the obtained results were analyzed using FlowJo software (Treestar).
結果を図3に示す。図3(A)はcPD1に対するラットモノクローナル抗体(anti-cPD1 mAb)とNRK/cPD1との結合を調べた結果であり、図3(B)はcPDL1に対するラットモノクローナル抗体(anti-cPD-L1 mAb)とNRK/cPDL1との結合を調べた結果である。横軸は作製した抗体に対する蛍光標識二次抗体の蛍光強度、縦軸は各ラットモノクローナル抗体の濃度を示す。図3に示すように、いずれのラットモノクローナル抗体を用いた場合でも蛍光強度が増加しており、cPD1に対するラットモノクローナル抗体である3B7-D9、4F12-E6はNRK/cPD1と結合し、cPDL1に対するラットモノクローナル抗体であるH7-9、G11-6は、NRK/cPDL1に結合することが確認された。すなわち、3B7-D9、4F12-E6は抗cPD1抗体であり、H7-9、G11-6は、抗cPDL1抗体であることが明らかとなった。 (result)
The results are shown in FIG. FIG. 3 (A) shows the results of examining the binding of rat monoclonal antibody (anti-cPD1 mAb) against cPD1 and NRK / cPD1, and FIG. 3 (B) shows the rat monoclonal antibody against cPDL1 (anti-cPD-L1 mAb). It is the result of having investigated the coupling | bonding of NRK / cPDL1. The horizontal axis represents the fluorescence intensity of the fluorescently labeled secondary antibody with respect to the prepared antibody, and the vertical axis represents the concentration of each rat monoclonal antibody. As shown in FIG. 3, the fluorescence intensity increased when any of the rat monoclonal antibodies was used, and 3B7-D9 and 4F12-E6, which are rat monoclonal antibodies against cPD1, bind to NRK / cPD1 and rat against cPDL1. Monoclonal antibodies H7-9 and G11-6 were confirmed to bind to NRK / cPDL1. That is, it was revealed that 3B7-D9 and 4F12-E6 are anti-cPD1 antibodies, and H7-9 and G11-6 are anti-cPDL1 antibodies.
1.cPD1とヒトIgFc領域との融合タンパク質、ヒトのPD-L1(hPDL1)とヒトIgFc領域との融合タンパク質の作製
(hPDL1発現プラスミドの構築)
hPDL1発現プラスミドを構築するため、ヒトのバーキットリンパ腫細胞株(Raji)由来のcDNAをテンプレートとし、フォワードプライマー(YTM1150:配列番号54)とリバースプライマー(YTM1151:配列番号55)を用いてhPDL1を増幅した。PCRによる増幅は上記実施例1と同様に行った。増幅したPCR産物をpBluescript SK(-)ベクターのSmaI部位に導入した。このプラスミドをEcoRIとNotIで切断し、得られた断片をpMxs-IPベクターのEcoRIとNotI部位に連結し、hPDL1発現プラスミドであるpMx-IP-hPDL1#21を作製した。 [Binding inhibition test of PD-1 and PD-L1 by rat monoclonal antibody]
1. Preparation of fusion protein of cPD1 and human IgFc region, and preparation of fusion protein of human PD-L1 (hPDL1) and human IgFc region (construction of hPDL1 expression plasmid)
In order to construct an hPDL1 expression plasmid, cDNA from human Burkitt lymphoma cell line (Raji) was used as a template and hPDL1 was amplified using a forward primer (YTM1150: SEQ ID NO: 54) and a reverse primer (YTM1151: SEQ ID NO: 55) did. Amplification by PCR was performed in the same manner as in Example 1 above. The amplified PCR product was introduced into the SmaI site of the pBluescript SK (−) vector. This plasmid was digested with EcoRI and NotI, and the resulting fragment was ligated to the EcoRI and NotI sites of the pMxs-IP vector to prepare pMx-IP-
cPD1又はhPDL1の細胞外領域と、ヒトIgG2 Fc領域との融合タンパク質とを発現するベクターを構築した。かかる発現ベクターを作製するために、実施例1で作製したpMx-IP-cPD1-FLをテンプレートとしてフォワードプライマー(YTM1153:配列番号56)とリバースプライマー(YTM1154:配列番号57)を用いてPCRを行うことでcPD1の細胞外領域を増幅し、上述で作製したpMx-IP-hPDL1#21をテンプレートとしてフォワードプライマー(YTM1157:配列番号58)とリバースプライマー(YTM1158:配列番号59)を用いてPCRを行うことでhPDL1の細胞外領域を増幅した。それぞれのPCR産物は、cPD1についてはBamHI、hPDL1についてはBglIIで切断し、pFUSE-hIgG2-Fc2ベクター(Invivogen社製)のEcoRVとBgIII部位にクローニングし、cPD1の細胞外領域と、ヒトIgG2 Fc領域との融合タンパク質とを発現するベクター(pFUSE-cPD1-hIg#2)、hPDL1の細胞外領域と、ヒトIgG2 Fc領域との融合タンパク質とを発現するベクター(pFUSE-hPDL1-hIg#9)を作製した。 (Fusion protein expression vector production)
A vector expressing a fusion protein of the extracellular region of cPD1 or hPDL1 and the human IgG2 Fc region was constructed. In order to prepare such an expression vector, PCR is performed using the forward primer (YTM1153: SEQ ID NO: 56) and reverse primer (YTM1154: SEQ ID NO: 57) using the pMx-IP-cPD1-FL prepared in Example 1 as a template. As a result, the extracellular region of cPD1 is amplified, and PCR is performed using the forward primer (YTM1157: SEQ ID NO: 58) and reverse primer (YTM1158: SEQ ID NO: 59) using the pMx-IP-
上述で作製したベクターpFUSE-cPD1-hIg#2、pFUSE-hPDL1-hIg#9、又は空ベクターのpFUSE-hIgG2-Fc2をHEK293T細胞株にトランスフェクトした。まず、トランスフェクションを行う1日前に、2×106個のHEK293T細胞を4つの10cmディッシュに播種した。次に、7.5μgの各ベクターと30μlの1mg/ml PEI Maxを含む375μlのOPTI-MEMを混合して室温で15分インキュベートし、細胞に加えた。トランスフェクションから24時間後に、培地をGIT無血清培地(和光純薬工業社製)に置換し、さらに細胞を48時間培養した。4日目と8日目の各トランスフェクト細胞から上澄みを集め、rProtein A agarose(GE healthcare社製)によって精製した。続いて、可溶性タンパク質を透析によって脱塩し、cPD1の細胞外領域とhIgG2 Fc領域との融合タンパク質(cPD1-hIg)、及び、hPDL1の細胞外領域とhIgG2 Fc領域との融合タンパク質(hPDL1-hIg)を作製した。上記融合タンパク質の純度は、SDS-PAGEとウェスタンブロッティングによって確認した。 (Production and purification of fusion protein)
The HEK293T cell line was transfected with the vector pFUSE-cPD1-
後述するラットモノクローナル抗体によるPD-1とPD-L1との阻害試験の予備試験として、hPDL1-hIgとNRK/cPD1との結合、又はcPD1-hIgとNRK/cPDL1との結合を、上記フローサイトメトリー解析と同様の方法で調べた。hPDL1-hIg、cPD1-hIgの濃度は0、0.04、0.156、0.625、2.5、10、40μg/mlとし、NRK/cPD1(2×105個)又はNRK/cPDL1(2×105個)を用いた。結果を図4に示す。図4(A)はhPDL1-hIgとNRK/cPD1との結合を調べた結果であり、図4(B)はcPD1-hIgとNRK/cPDL1との結合を調べた結果である。横軸は作製した融合タンパク質に対する蛍光標識二次抗体の蛍光強度、縦軸はhPDL1-hIg又はcPD1-hIgの濃度を示す。図4に示すように、hPDL1-hIgはNRK/cPD1に結合し、cPD1-hIgはNRK/cPDL1に結合することが明らかとなった。 2. Binding test of PD-1 and PD-L1 As a preliminary test of inhibition test of PD-1 and PD-L1 by rat monoclonal antibody described later, binding of hPDL1-hIg and NRK / cPD1, or cPD1-hIg and NRK The binding to / cPDL1 was examined by the same method as in the flow cytometry analysis. The concentrations of hPDL1-hIg and cPD1-hIg were 0, 0.04, 0.156, 0.625, 2.5, 10, 40 μg / ml, and NRK / cPD1 (2 × 10 5 ) or NRK / cPDL1 ( 2 × 10 5 ) was used. The results are shown in FIG. FIG. 4A shows the result of examining the binding between hPDL1-hIg and NRK / cPD1, and FIG. 4B shows the result of examining the binding between cPD1-hIg and NRK / cPDL1. The horizontal axis represents the fluorescence intensity of the fluorescently labeled secondary antibody for the prepared fusion protein, and the vertical axis represents the concentration of hPDL1-hIg or cPD1-hIg. As shown in FIG. 4, it was revealed that hPDL1-hIg binds to NRK / cPD1, and cPD1-hIg binds to NRK / cPDL1.
(フローサイトメトリー解析)
(1)NRK/cPD1に、cPD1に対するラットモノクローナル抗体(3B7-D9、4F12-E6)を反応させ、その後hPDL1-hIgを反応させることで、hPDL1-hIgとNRK/cPD1との結合をcPD1に対するラットモノクローナル抗体が阻害するか、(2)NRK/cPDL1に、cPDL1に対するラットモノクローナル抗体(H7-9、G11-6)を反応させ、その後cPD1-hIgを反応させることで、cPD1-hIgとNRK/cPDL1との結合をcPDL1に対するラットモノクローナル抗体が阻害するか、又は(3)cPD1に対するラットモノクローナル抗体(3B7-D9、4F12-E6)とcPD1-hIgを反応させ、その後その混合反応物をNRK/cPDL1に反応させることで、cPD1-hIgとNRK/cPDL1との結合をcPD1に対するラットモノクローナル抗体が阻害するか、の3点をそれぞれ調べた。各抗体によるPD-1とPD-L1との結合阻害は上記フローサイトメトリー解析と同様に調べた。各ラットモノクローナル抗体の濃度は0、0.04、0.156、0.625、2.5、10μg/mlとし、hPDL1-hIg、cPD1-hIgの濃度は40μg/mlとし、NRK/cPD1(2×105個)又はNRK/cPDL1(2×105個)を用いた。 3. Binding inhibition test of PD-1 and PD-L1 with rat monoclonal antibody (flow cytometry analysis)
(1) By reacting NRK / cPD1 with a rat monoclonal antibody against cPD1 (3B7-D9, 4F12-E6), and then reacting with hPDL1-hIg, the binding of hPDL1-hIg and NRK / cPD1 to rat against cPD1 (2) By reacting NRK / cPDL1 with rat monoclonal antibodies against cPDL1 (H7-9, G11-6) and then reacting with cPD1-hIg, cPD1-hIg and NRK / cPDL1 Or the rat monoclonal antibody against cPDL1 inhibits the binding with (3) the rat monoclonal antibody against cPD1 (3B7-D9, 4F12-E6) and cPD1-hIg, and the mixed reaction product is then converted to NRK / cPDL1. React It is examined CPD1-hIg and NRK / cPDL1 the coupling or rat monoclonal antibodies against CPD1 is inhibition of the three points, respectively. The inhibition of the binding between PD-1 and PD-L1 by each antibody was examined in the same manner as in the flow cytometry analysis. The concentration of each rat monoclonal antibody was 0, 0.04, 0.156, 0.625, 2.5, 10 μg / ml, the concentration of hPDL1-hIg, cPD1-hIg was 40 μg / ml, and NRK / cPD1 (2 × 10 5 ) or NRK / cPDL1 (2 × 10 5 ) was used.
結果を図5、6に示す。図5(A)はcPD1に対するラットモノクローナル抗体によるhPDL1-hIgとNRK/cPD1との結合阻害を調べた結果であり、図5(B)はcPDL1に対するラットモノクローナル抗体によるcPD1-hIgとNRK/cPDL1との結合阻害を調べた結果であり、図6はcPD1に対するラットモノクローナル抗体によるcPD1-hIgとNRK/cPDL1との結合阻害を調べた結果である。横軸は作製した抗体に対する蛍光標識二次抗体の蛍光強度、縦軸左は各ラットモノクローナル抗体の濃度、縦軸右はhPDL1-hIg又はcPD1-hIgの有り(+)/無し(-)を示す。図5(A)、(B)、図6に示すように、hPDL1-hIgとNRK/cPD1との結合や、cPD1-hIgとNRK/cPDL1との結合をcPD1に対するラットモノクローナル抗体である3B7-D9、4F12-E6が阻害し、cPD1-hIgとNRK/cPDL1との結合をcPDL1に対するラットモノクローナル抗体であるH7-9、G11-6が阻害することが明らかとなった。 (result)
The results are shown in FIGS. FIG. 5 (A) shows the results of examining the inhibition of binding between hPDL1-hIg and NRK / cPD1 by a rat monoclonal antibody against cPD1, and FIG. 5 (B) shows the results of cPD1-hIg and NRK / cPDL1 produced by a rat monoclonal antibody against cPDL1. FIG. 6 shows the results of examining the binding inhibition between cPD1-hIg and NRK / cPDL1 by a rat monoclonal antibody against cPD1. The abscissa indicates the fluorescence intensity of the fluorescently labeled secondary antibody with respect to the prepared antibody, the ordinate indicates the concentration of each rat monoclonal antibody, and the ordinate indicates the presence (+) / absence (-) of hPDL1-hIg or cPD1-hIg. . As shown in FIGS. 5 (A), (B) and FIG. 6, the binding between hPDL1-hIg and NRK / cPD1 or the binding between cPD1-hIg and NRK / cPDL1 is 3B7-D9 which is a rat monoclonal antibody against cPD1. It was revealed that 4F12-E6 inhibited, and the binding of cPD1-hIg and NRK / cPDL1 was inhibited by rat monoclonal antibodies H7-9 and G11-6 against cPDL1.
トータルRNAを実施例1で得られた各ハイブリドーマ細胞株から単離し、全ての可変領域と定常領域の5’領域を含む、免疫グロブリン重鎖(IgG2a)の塩基配列とκ軽鎖の塩基配列を5’RACE PCR法によって得た。 [Determination of the base sequences of the heavy and light chains of rat monoclonal antibody]
Total RNA was isolated from each hybridoma cell line obtained in Example 1, and the nucleotide sequence of the immunoglobulin heavy chain (IgG2a) and the nucleotide sequence of the kappa light chain including the 5 ′ region of all variable regions and constant regions were determined. Obtained by 5'RACE PCR method.
3頭のイヌ(A,B,C)より末梢血単核細胞(PBMC)を回収し、PBMCを96ウェル丸底プレート中にウェル当たり2×105個、isotype(ラットIgG2a:eBioscience社製)、PD-1に対するラットモノクローナル抗体(anti-PD-1:4F12-E6)、又はcPDL1に対するラットモノクローナル抗体(anti-PD-L1:G11-6)を10μg/mlの濃度となるように加えて、さらにコンカナバリンA(ConA)を5μg/mlとなるように加えて3日間刺激培養し、得られた培養上清中のイヌIFN-γをcanine IFN-gamma DuoSet ELISA(R&D社製)により測定した。結果を図7に示す。 [Enhanced production of IFN-γ]
Peripheral blood mononuclear cells (PBMC) were collected from 3 dogs (A, B, C), and 2 × 10 5 PBMCs per well in a 96-well round bottom plate, isotype (rat IgG2a: manufactured by eBioscience) A rat monoclonal antibody against PD-1 (anti-PD-1: 4F12-E6) or a rat monoclonal antibody against cPDL1 (anti-PD-L1: G11-6) was added to a concentration of 10 μg / ml, Furthermore, concanavalin A (ConA) was added to 5 μg / ml and stimulated for 3 days, and canine IFN-γ in the obtained culture supernatant was measured by canine IFN-gamma DuoSet ELISA (manufactured by R & D). The results are shown in FIG.
イヌPBMCをPMA/ionomycin又はConA存在下で3日間培養し、PBMCを回収後、CD3陽性分画(T細胞)におけるPD-1、PD-L1の発現を、cPD1に対するラットモノクローナル抗体(4F12-E6)又はcPDL1に対するラットモノクローナル抗体(G11-6)を用いてフローサイトメトリー解析した。結果を図8に示す。 [Induction of expression of PD-1 or PD-L1 in the presence of PMA (Phorbol-12-myristate-13-acetate) / ionomycin (iono) or ConA]
Canine PBMC was cultured in the presence of PMA / ionomycin or ConA for 3 days, and after PBMCs were collected, the expression of PD-1 and PD-L1 in the CD3-positive fraction (T cells) was compared with the rat monoclonal antibody against cPD1 (4F12-E6 ) Or a rat monoclonal antibody (G11-6) against cPDL1 was analyzed by flow cytometry. The results are shown in FIG.
イヌPBMCより磁気ビーズにより分離したCD14陽性単球をIL-4及びGM-CSF存在下で6日間培養し、未成熟樹状細胞を誘導した。未成熟樹状細胞であることは、MHC ClassII抗体(eBioscience社製)を同時に染色することで確認した。得られた未成熟樹状細胞におけるPD-1又はPD-L1の発現をcPD1に対するラットモノクローナル抗体(4F12-E6)、又はcPDL1に対するラットモノクローナル抗体(G11-6)を用いてフローサイトメトリー解析した結果を図9に示す。 [Induction of PD-1 or PD-L1 expression in the presence of IL-4 or GM-CSF]
CD14 positive monocytes separated from canine PBMC by magnetic beads were cultured in the presence of IL-4 and GM-CSF for 6 days to induce immature dendritic cells. The immature dendritic cells were confirmed by staining with MHC Class II antibody (manufactured by eBioscience) at the same time. Results of flow cytometry analysis of PD-1 or PD-L1 expression in the obtained immature dendritic cells using a rat monoclonal antibody against cPD1 (4F12-E6) or a rat monoclonal antibody against cPDL1 (G11-6) Is shown in FIG.
Claims (7)
- 配列番号1に示されるアミノ酸配列からなるイヌPD-1に特異的に結合する、以下の(a)又は(b)記載の抗イヌPD-1抗体。
(a)配列番号2に示されるアミノ酸配列、又は配列番号2に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号3に示されるアミノ酸配列、又は配列番号3に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
(b)配列番号4に示されるアミノ酸配列、又は配列番号4に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号5に示されるアミノ酸配列、又は配列番号5に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体; The anti-canine PD-1 antibody described in (a) or (b) below, which specifically binds to canine PD-1 consisting of the amino acid sequence shown in SEQ ID NO: 1.
(A) the amino acid sequence shown in SEQ ID NO: 2, or the heavy chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 2, and the amino acid sequence shown in SEQ ID NO: 3, or An anti-canine PD-1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 3;
(B) the heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 4, or the amino acid sequence shown in SEQ ID NO: 4 having 90% or more identity, and the amino acid sequence shown in SEQ ID NO: 5, or An anti-canine PD-1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 5; - 配列番号6に示されるアミノ酸配列からなるイヌPD-L1に特異的に結合する、以下の(c)又は(d)記載の抗イヌPD-L1抗体。
(c)配列番号7に示されるアミノ酸配列、又は配列番号7に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号8に示されるアミノ酸配列、又は配列番号8に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
(d)配列番号9に示されるアミノ酸配列、又は配列番号9に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する重鎖可変領域、及び配列番号10に示されるアミノ酸配列、又は配列番号10に示されるアミノ酸配列と90%以上の同一性を有するアミノ酸配列を有する軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体; The anti-canine PD-L1 antibody described in (c) or (d) below, which specifically binds to canine PD-L1 having the amino acid sequence shown in SEQ ID NO: 6.
(C) the amino acid sequence shown in SEQ ID NO: 7, or the heavy chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 7, and the amino acid sequence shown in SEQ ID NO: 8, or An anti-canine PD-L1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 8;
(D) the amino acid sequence shown in SEQ ID NO: 9, or the heavy chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 9, and the amino acid sequence shown in SEQ ID NO: 10, or An anti-canine PD-L1 antibody comprising a light chain variable region having an amino acid sequence having 90% or more identity with the amino acid sequence shown in SEQ ID NO: 10; - 配列番号1に示されるアミノ酸配列からなるイヌPD-1に特異的に結合する、以下の(e)又は(f)記載の抗イヌPD-1抗体。
(e)配列番号11に示されるアミノ酸配列からなるCDR1、配列番号12に示されるアミノ酸配列からなるCDR2及び配列番号13に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号14に示されるアミノ酸配列からなるCDR1、配列番号15に示されるアミノ酸配列からなるCDR2及び配列番号16に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体;
(f)配列番号17に示されるアミノ酸配列からなるCDR1、配列番号18に示されるアミノ酸配列からなるCDR2及び配列番号19に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号20に示されるアミノ酸配列からなるCDR1、配列番号21に示されるアミノ酸配列からなるCDR2及び配列番号22に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-1抗体; The anti-canine PD-1 antibody described in (e) or (f) below, which specifically binds to canine PD-1 consisting of the amino acid sequence shown in SEQ ID NO: 1.
(E) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 11, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 12 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 13, An anti-canine PD-1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 15, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 16. antibody;
(F) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 18 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 19, An anti-canine PD-1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 21, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 22 antibody; - 配列番号6に示されるアミノ酸配列からなるイヌPD-L1に特異的に結合する、以下の(g)又は(h)記載の抗イヌPD-L1抗体。
(g)配列番号23に示されるアミノ酸配列からなるCDR1、配列番号24に示されるアミノ酸配列からなるCDR2及び配列番号25に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号26に示されるアミノ酸配列からなるCDR1、配列番号27に示されるアミノ酸配列からなるCDR2及び配列番号28に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体;
(h)配列番号29に示されるアミノ酸配列からなるCDR1、配列番号30に示されるアミノ酸配列からなるCDR2及び配列番号31に示されるアミノ酸配列からなるCDR3を含む重鎖可変領域と、配列番号32に示されるアミノ酸配列からなるCDR1、配列番号33に示されるアミノ酸配列からなるCDR2及び配列番号34に示されるアミノ酸配列からなるCDR3を含む軽鎖可変領域を備えたことを特徴とする抗イヌPD-L1抗体; The anti-canine PD-L1 antibody described in (g) or (h) below, which specifically binds to canine PD-L1 consisting of the amino acid sequence shown in SEQ ID NO: 6.
(G) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 23, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 24 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 25; An anti-canine PD-L1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 27, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 28 antibody;
(H) a heavy chain variable region comprising CDR1 consisting of the amino acid sequence shown in SEQ ID NO: 29, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 30 and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 31, An anti-canine PD-L1 comprising a light chain variable region comprising CDR1 consisting of the amino acid sequence shown, CDR2 consisting of the amino acid sequence shown in SEQ ID NO: 33, and CDR3 consisting of the amino acid sequence shown in SEQ ID NO: 34 antibody; - 請求項1~4のいずれか記載の抗体を含有することを特徴とするイヌPD-1とイヌPD-L1との結合阻害剤。 A binding inhibitor of canine PD-1 and canine PD-L1, comprising the antibody according to any one of claims 1 to 4.
- 請求項1~4のいずれか記載の抗体を用いることを特徴とするイヌPD-1とイヌPD-L1との結合阻害方法。 A method for inhibiting the binding between canine PD-1 and canine PD-L1, wherein the antibody according to any one of claims 1 to 4 is used.
- 請求項1~4のいずれか記載の抗体をコードする遺伝子。 A gene encoding the antibody according to any one of claims 1 to 4.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016532441A JP6279733B2 (en) | 2014-07-09 | 2015-07-08 | Anti-canine PD-1 antibody or anti-canine PD-L1 antibody |
US15/320,412 US10280223B2 (en) | 2014-07-09 | 2015-07-08 | Anti-canine PD-1 antibody or anti-canine PD-L1 antibody |
EP15819249.2A EP3168236B1 (en) | 2014-07-09 | 2015-07-08 | Anti-canine pd-1 antibody or anti-canine pd-l1 antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-140982 | 2014-07-09 | ||
JP2014140982 | 2014-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016006241A1 true WO2016006241A1 (en) | 2016-01-14 |
Family
ID=55063893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/003444 WO2016006241A1 (en) | 2014-07-09 | 2015-07-08 | Anti-canine pd-1 antibody or anti-canine pd-l1 antibody |
Country Status (4)
Country | Link |
---|---|
US (1) | US10280223B2 (en) |
EP (1) | EP3168236B1 (en) |
JP (1) | JP6279733B2 (en) |
WO (1) | WO2016006241A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106632676A (en) * | 2017-01-20 | 2017-05-10 | 新乡学院 | Mouse anti-swine PD-L1 (Programmed Death 1 Ligand 1) monoclonal antibody and application thereof |
US9920123B2 (en) | 2008-12-09 | 2018-03-20 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
US9944704B2 (en) | 2013-12-20 | 2018-04-17 | Intervet Inc. | Antibodies against canine PD-1 |
CN108350082A (en) * | 2016-06-13 | 2018-07-31 | 爱迈博 | PD-L1 antibody and application thereof |
WO2018181064A1 (en) * | 2017-03-27 | 2018-10-04 | 国立大学法人北海道大学 | Anti-pd-l1 antibody for detecting pd-l1 |
US10336824B2 (en) | 2015-03-13 | 2019-07-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof |
WO2020103885A1 (en) * | 2018-11-19 | 2020-05-28 | Beijing Biocytogen Co., Ltd | Anti-pd-1 antibodies and uses thereof |
US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10348432B2 (en) | 2013-06-11 | 2019-07-09 | Texas Instruments Incorporated | Network signaling for network-assisted interference cancellation and suppression |
WO2016050721A1 (en) | 2014-09-30 | 2016-04-07 | Intervet International B.V. | Pd-l1 antibodies binding canine pd-l1 |
KR20180040138A (en) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of using them |
BR112018008904A2 (en) | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | antibodies specifically binding to tim-3 and their uses |
CN109452229B (en) * | 2018-11-19 | 2021-10-22 | 百奥赛图(北京)医药科技股份有限公司 | Preparation method and application of caninized PD-1 gene modified animal model |
CN112920276B (en) * | 2019-06-03 | 2021-11-12 | 北京希诺谷生物科技有限公司 | Anti-canine PD-1 antibody and preparation method thereof |
CA3177921A1 (en) * | 2020-05-04 | 2021-11-11 | Inhibrx, Inc. | Canine pd-1-binding polypeptides and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013173223A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI2206517T3 (en) | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
KR101050829B1 (en) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody |
-
2015
- 2015-07-08 US US15/320,412 patent/US10280223B2/en active Active
- 2015-07-08 WO PCT/JP2015/003444 patent/WO2016006241A1/en active Application Filing
- 2015-07-08 JP JP2016532441A patent/JP6279733B2/en active Active
- 2015-07-08 EP EP15819249.2A patent/EP3168236B1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013173223A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
Non-Patent Citations (2)
Title |
---|
MEAEKAWA ET AL.: "Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade", PLOS ONE, vol. 9, no. Issue 6, June 2014 (2014-06-01), pages e98415, XP055179324 * |
See also references of EP3168236A4 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9920123B2 (en) | 2008-12-09 | 2018-03-20 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
US10711061B2 (en) | 2013-12-20 | 2020-07-14 | Intervet Inc. | Antibodies against canine PD-1 |
US11248047B2 (en) | 2013-12-20 | 2022-02-15 | Intervet Inc. | Caninized antibodies |
US10023636B2 (en) | 2013-12-20 | 2018-07-17 | Intervet Inc. | Caninized murine antibodies to human PD-1 |
US9944704B2 (en) | 2013-12-20 | 2018-04-17 | Intervet Inc. | Antibodies against canine PD-1 |
US10927172B2 (en) | 2013-12-20 | 2021-02-23 | Intervet Inc. | Caninized murine antibodies to human PD-1 |
US10106607B2 (en) | 2013-12-20 | 2018-10-23 | Intervet Inc. | Caninized antibodies |
US11680097B2 (en) | 2013-12-20 | 2023-06-20 | Intervet Inc. | Antibodies against canine PD-1 |
US10336824B2 (en) | 2015-03-13 | 2019-07-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof |
US11174316B2 (en) | 2015-03-13 | 2021-11-16 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
US10669339B2 (en) | 2015-03-13 | 2020-06-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
CN108350082B (en) * | 2016-06-13 | 2021-09-24 | 天境生物科技(上海)有限公司 | PD-L1 antibodies and uses thereof |
CN108350082A (en) * | 2016-06-13 | 2018-07-31 | 爱迈博 | PD-L1 antibody and application thereof |
CN106632676A (en) * | 2017-01-20 | 2017-05-10 | 新乡学院 | Mouse anti-swine PD-L1 (Programmed Death 1 Ligand 1) monoclonal antibody and application thereof |
CN106632676B (en) * | 2017-01-20 | 2020-05-29 | 新乡学院 | Mouse-anti-pig PD-L1 monoclonal antibody and application thereof |
RU2758723C2 (en) * | 2017-03-27 | 2021-11-01 | Нэшнл Юниверсити Корпорейшн Хоккайдо Юниверсити | Anti-pd-l1 antibody for pd-l1 detection |
US10865246B2 (en) | 2017-03-27 | 2020-12-15 | Fuso Pharmaceutical Industries, Ltd. | Anti-PD-L1 antibody for detecting PD-L1 |
US11697686B2 (en) | 2017-03-27 | 2023-07-11 | National University Corporation Hokkaido University | Anti-PD-L1 antibody for detecting PD-L1 |
KR102402398B1 (en) | 2017-03-27 | 2022-05-25 | 국립대학법인 홋가이도 다이가쿠 | Anti-PD-L1 Antibody for PD-L1 Detection |
KR20190132651A (en) * | 2017-03-27 | 2019-11-28 | 국립대학법인 홋가이도 다이가쿠 | Anti-PD-L1 Antibody for PD-L1 Detection |
WO2018181064A1 (en) * | 2017-03-27 | 2018-10-04 | 国立大学法人北海道大学 | Anti-pd-l1 antibody for detecting pd-l1 |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
US11352429B2 (en) | 2018-11-19 | 2022-06-07 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-PD-1 antibodies and uses thereof |
WO2020103885A1 (en) * | 2018-11-19 | 2020-05-28 | Beijing Biocytogen Co., Ltd | Anti-pd-1 antibodies and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JPWO2016006241A1 (en) | 2017-04-27 |
US20170158764A1 (en) | 2017-06-08 |
EP3168236A1 (en) | 2017-05-17 |
EP3168236A4 (en) | 2018-01-10 |
EP3168236B1 (en) | 2019-09-04 |
US10280223B2 (en) | 2019-05-07 |
JP6279733B2 (en) | 2018-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6279733B2 (en) | Anti-canine PD-1 antibody or anti-canine PD-L1 antibody | |
US11198730B2 (en) | Anti-LAG-3 antibody | |
KR102512934B1 (en) | Chimeric antigen receptors targeting BCMA and methods for their use | |
TWI744242B (en) | Antibody constructs for egfrviii and cd3 | |
JP7361610B2 (en) | Anti-PD-L1 antibody and its use | |
CN114774444A (en) | Universal chimeric antigen receptor expressing immune cells, methods of making and therapeutic uses thereof | |
US9676858B2 (en) | Human bispecific EGFRvIII antibody and CD3 engaging molecules | |
JP2021519610A (en) | Multivalent antibody | |
EP3019532B1 (en) | Human bispecific egfrviii antibody engaging molecules | |
TW201938586A (en) | Continuous manufacturing process for bispecific antibody products | |
JP2019193652A (en) | Antibodies against prostate-specific stem cell antigen and uses thereof | |
US20240050568A1 (en) | Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof | |
CN115812081A (en) | anti-CTLA-4 antibodies and uses thereof | |
IL285909B2 (en) | Anti-bcma single chain variable fragments | |
CN113045661B (en) | Novel anti-CD 4 antibodies | |
RU2744862C2 (en) | Antibody against pd-l1 | |
WO2015172341A1 (en) | Bispecific antibody for glypican-3 and t cell antigen | |
WO2023273762A1 (en) | Spatial conformational epitope mediating efficient retention of cd3 within cells and application thereof | |
WO2022152282A1 (en) | Anti-human cd22 monoclonal antibodies and use thereof | |
US20230159652A1 (en) | Transferrin receptor 1 targeting for carcinogenesis prevention | |
WO2020078149A1 (en) | Anti-cd137 antibody and uses thereof | |
TW202340240A (en) | Multi-specific antibody and its pharmaceutical uses | |
CN116568709A (en) | CD 5-targeting fully human antibodies, fully human Chimeric Antigen Receptor (CAR) and uses thereof | |
KR20230154235A (en) | Antibodies against NKp46 and their applications | |
JP2023549977A (en) | Chimeric antigen receptor containing anti-mesothelin scFv and its uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15819249 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016532441 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015819249 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015819249 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15320412 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |